The following is a summary of "Transit time flow management as a management strategy in high-risk groups undergoing coronary ...

Compared with other studies, the differences in outcomes between percutaneous coronary intervention (PCI) and coronary artery ...

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today they have entered a non-binding Memorandum of ...

In current European and American revascularization guidelines, RA grafts are now strongly endorsed as the second conduit for CABG based on easy harvesting and relative greater patency over time, among ...

Coronary artery bypass grafting is a more invasive procedure where surgeons use blood vessels from another part of the body ...

Actor and director Manoj Bharathiraja's death has created shockwaves in the film industry after the 48-year-old died of a ...

An investigational monoclonal antibody called bentracimab can safely and effectively reverse potentially catastrophic ...

FDA Approval: The FDA granted full approval for Symvess on December 19, 2024 for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid ...

A subgroup analysis of the FAME 3 randomized clinical trial has revealed that the relative benefit of Coronary Artery Bypass ...

Q4 2024 Earnings Call Transcript March 31, 2025 Cytosorbents Corporation beats earnings expectations. Reported EPS is $-0.03, ...

The Germany-based Journal of Cardiothoracic Surgery say it is a serious complication with a low survival rate..Manoj ...